Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1990 1
1991 3
1993 3
1995 1
1996 1
1997 1
2002 1
2003 1
2004 2
2005 1
2006 2
2007 1
2008 1
2009 1
2010 1
2011 1
2012 1
2014 5
2015 6
2016 3
2017 6
2018 7
2019 4
2020 2
2022 9
2023 5
2024 7
2025 10
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean h ezazadeh (5,206,601 results)?
Bis[(2-amino-phen-yl)methanol-κN,O]bis-(nitrato-κO)cobalt(II).
Esmhosseini M, Rezazadeh M. Esmhosseini M, et al. Acta Crystallogr Sect E Struct Rep Online. 2010 Aug 18;66(Pt 9):m1126. doi: 10.1107/S1600536810032381. Acta Crystallogr Sect E Struct Rep Online. 2010. PMID: 21588529 Free PMC article.
The asymmetric unit of the title compound, [Co(NO(3))(2)(C(7)H(9)NO)(2)], contains one-half of the mol-ecule. The Co(II) atom (site symmetry 2) is six-coordinate in a distorted octahedral configuration bonded by two N and two O atoms from two (2-amino-phen-yl)methanol liga …
The asymmetric unit of the title compound, [Co(NO(3))(2)(C(7)H(9)NO)(2)], contains one-half of the mol-ecule. The Co(II) atom (site s …
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group. Siefker-Radtke AO, et al. Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030333 Clinical Trial.
Lifestyle and psychosocial factors in inflammatory bowel disease: Prevalence, impact, motivation, and support needs.
Demers K, Hendrix EMB, Ardabili AR, Bredero QM, van Bodegraven AA, van der Horst D, Jonkers DMAE, Kimman ML, Mujagic Z, Romberg-Camps MJ, Römkens TEH, Scherpenzeel MP, Schroevers MJ, Stassen LPS, West RL, Dijkstra G, Pierik MJ. Demers K, et al. PLoS One. 2025 Aug 29;20(8):e0331092. doi: 10.1371/journal.pone.0331092. eCollection 2025. PLoS One. 2025. PMID: 40880377 Free PMC article.
Designing a broad-spectrum integrative approach for cancer prevention and treatment.
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Moha… See abstract for full author list ➔ Block KI, et al. Semin Cancer Biol. 2015 Dec;35 Suppl(Suppl):S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Semin Cancer Biol. 2015. PMID: 26590477 Free PMC article. Review.
Evaluation and selection of a lead diabody for interferon-γ PET imaging.
Rezazadeh F, Ramos N, Saliganan AD, Barr S, Peraino N, Schomburg F, Rancour D, Viola NT. Rezazadeh F, et al. Nucl Med Biol. 2022 Nov-Dec;114-115:162-167. doi: 10.1016/j.nucmedbio.2022.06.001. Epub 2022 Jun 17. Nucl Med Biol. 2022. PMID: 35753939 Free PMC article.
All tracers except for [(89)Zr]Zr-DFO-NCS-anti-IFN-gamma HL-9 exhibited comparable immunoreactivities (>90 %) to the radiolabeled parent mAb (95.8 %). At 24 h post-labeling, the IRF values were retained except for the HL-13 construct. Imaging scans and tissue distributi …
All tracers except for [(89)Zr]Zr-DFO-NCS-anti-IFN-gamma HL-9 exhibited comparable immunoreactivities (>90 %) to the radiolabeled parent …
85 results